CIK 0001850119
- Emerging growth company
Century Therapeutics, Inc.
Sign in to watch- Ticker
- IPSC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 842040295
- Phone
- +1 215-981-4000
- Business address
- 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,212
- in 5 filings
Net −$10,212. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-12 | Levitsky Hyam President of R&D | Grant or award · Stock Option (right to buy) | +131,250 | 131,250 | ||
| 2023-04-11 | Russotti Gregory Chief Technology Officer | Grant or award · Stock Option (right to buy) | +318,750 | 318,750 | ||
| 2023-04-03 | Borges Luis Chief Scientific Officer | Exercise or conversion | +7,452 | $1.03 | $8K | 256,535 |
| 2023-04-03 | Borges Luis Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −7,452 | 0 | ||
| 2023-03-23 | Borges Luis Chief Scientific Officer | Exercise or conversion | +220,930 | $1.03 | $228K | 264,680 |
| 2023-03-23 | Borges Luis Chief Scientific Officer | Sale | −15,597 | $3.55 | $55K | 249,083 |
| 2023-03-23 | Borges Luis Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −220,930 | 7,452 | ||
| 2023-03-22 | Borges Luis Chief Scientific Officer | Exercise or conversion | +65,698 | $1.03 | $68K | 109,448 |
| 2023-03-22 | Borges Luis Chief Scientific Officer | Sale | −65,698 | $3.72 | $245K | 43,750 |
| 2023-03-22 | Borges Luis Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −65,698 | 228,382 | ||
| 2023-03-21 | Borges Luis Chief Scientific Officer | Exercise or conversion | +63,616 | $1.03 | $66K | 107,366 |
| 2023-03-21 | Borges Luis Chief Scientific Officer | Sale | −63,616 | $3.77 | $240K | 43,750 |
| 2023-03-21 | Borges Luis Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −63,616 | 294,080 | ||
| 2023-02-02 | Flores Osvaldo Chief Executive Officer | Grant or award · Stock Option (right to buy) | +637,500 | 637,500 | ||
| 2023-02-02 | Flores Osvaldo Chief Executive Officer | Grant or award · Stock Option (right to buy) | +637,500 | 637,500 | ||
| 2023-02-02 | Carr Douglas VP Finance & Operations | Grant or award | +7,500 | 193,045 | ||
| 2023-02-02 | Carr Douglas VP Finance & Operations | Grant or award | +7,500 | 200,545 | ||
| 2023-02-02 | Carr Douglas VP Finance & Operations | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2023-02-02 | Carr Douglas VP Finance & Operations | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2023-02-02 | Russotti Gregory Chief Technology Officer | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 |
Page 9 of 12 · 233 trades